Anticancer Drugs Medicine Oncology Panitumumab Pharmacology Physiotherapy


In this article we will discuss Panitumumab
(Dosage Overview)

In this article, we will discuss Panitumumab (Dosage Overview). So, let’s get started.


Panitumumab is indicated as a single agent for the treatment of epidermal growth factor receptor (EGFR)-expressing, metastatic colorectal carcinoma (mCRC) with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.

The effectiveness of panitumumab as a single agent for the treatment of EGFR-expressing, metastatic colorectal carcinoma is based on progression-free survival. Currently, no data demonstrate an improvement in disease-related symptoms or increased survival with panitumumab.

Retrospective subset analyses of metastatic colorectal cancer trials have not shown a treatment benefit for panitumumab in patients whose tumors had KRAS mutations in codon 12 or 13. Use of panitumumab is not recommended for the treatment of colorectal cancer with these mutations.


Recommended Dose and Dose Modifications

The recommended dose of panitumumab is 6 mg/kg, administered as an intravenous infusion over 60 minutes, every 14 days. Doses higher than 1000 mg should be administered over 90 minutes. Appropriate medical resources for the treatment of severe infusion reactions should be available during panitumumab

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.